ARTICLE | Clinical News

Rebif recombinant interferon beta-1a regulatory update

December 17, 2001 8:00 AM UTC

Rebif is marketed to treat MS in Europe and Canada but cannot be marketed in the U.S. until mid-2003 due to the Orphan Drug status of Avonex. SRA said that under the terms of the Orphan Drug Act, a he...